2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatientsPatient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Figura N, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Christopherson K, Kim S, Locke F, Jain M, Robinson T. Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s85. DOI: 10.1016/j.ijrobp.2022.07.491.Peer-Reviewed Original ResearchMedian metabolic tumor volumeT-cell therapyRefractory large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaBRT patientsDisease burdenTotal disease burdenB-cell lymphomaField progressionRadiation therapyLocal controlClinical outcomesExact testChimeric antigen receptor T-cell therapyCAR T-cell infusionDistant-only failureDurable local controlLocal-only failureWorse disease burdenFuture prospective trialsT-cell infusionHigh-risk patientsKaplan-Meier methodLow disease burdenUpfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Yu H, Oliver D, Ahmed K. Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e14. DOI: 10.1016/j.ijrobp.2021.10.186.Peer-Reviewed Original ResearchDistant intracranial controlEGFR-positive NSCLCBrain metastasesRadiation therapyBM diagnosisOverall survivalLocal controlMultivariate analysisSingle-institution retrospective analysisGeneration tyrosine kinase inhibitorsCentral nervous system penetrationUpfront radiation therapyKaplan-Meier methodProportional hazards modelTyrosine kinase inhibitorsMATERIAL/METHODSIntracranial radiation therapyIntracranial controlUpfront treatmentDS-GPAClinical outcomesResults MedianRetrospective analysisTreatment groupsHazards model
2019
CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES
Mohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES. Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.Peer-Reviewed Original ResearchStereotactic radiotherapyMedian timeRenal cell carcinoma brain metastasesDistant brain failureStage IV RCCMedian overall survivalOptimal treatment sequenceCox regression modelStereotactic radiation therapyWarrants further investigationDistant brainEligible lesionsNivolumab administrationBrain metastasesConsecutive patientsOverall survivalClinical outcomesBrain failureKaplan-MeierRetrospective databaseHemorrhagic lesionsNivolumabRadiation therapyPatient basisPatientsOutcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab
Mohammadi H, Tolpin A, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Robinson T, Yu M. Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e82. DOI: 10.1016/j.ijrobp.2019.06.2349.Peer-Reviewed Original ResearchOA15 Clinical Outcomes of Breast Leptomeningeal Disease Treated with Intrathecal Trastuzumab, Intrathecal Chemotherapy, or Whole Brain Radiation Therapy
Figura N, Mohammadi H, Rizk V, Evernden B, Mokhtari S, Yu H, Robinson T, Etame A, Tran N, Diaz R, Soliman H, Han H, Sahebjam S, Forsyth P, Ahmed K. OA15 Clinical Outcomes of Breast Leptomeningeal Disease Treated with Intrathecal Trastuzumab, Intrathecal Chemotherapy, or Whole Brain Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e7. DOI: 10.1016/s0360-3016(19)30416-x.Peer-Reviewed Original Research
2018
Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel
Jain M, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Falchook A, Robinson T, Kim S, Locke F. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood 2018, 132: 4220. DOI: 10.1182/blood-2018-99-117133.Peer-Reviewed Original ResearchCytokine release syndromeAxi-cel therapyCAR-T infusionCy conditioningCase seriesT infusionTumor burdenAxicabtagene ciloleucelCAR TSpeakers bureauRadiation therapyRefractory diffuse large B-cell lymphoma patientsRefractory diffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyPatient experienced progressive diseaseSevere cytokine release syndromeDiffuse large B-cell lymphoma patientsDisease controlLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaAdvisory CommitteeLarge B-cell lymphomaCAR T cell efficacyExperienced progressive disease
2017
Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases
Savla B, Ahmed K, Yu M, Perez B, Dinan M, Mason N, Robinson T. Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e105. DOI: 10.1016/j.ijrobp.2017.06.842.Peer-Reviewed Original Research
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time